“Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?”. Regulatory Peptides128 (2): 159–65. (June 2005). doi:10.1016/j.regpep.2004.06.001. PMID15780435.
“Pancreatic safety of incretin-based drugs--FDA and EMA assessment”. The New England Journal of Medicine370 (9): 794–7. (February 2014). doi:10.1056/NEJMp1314078. PMID24571751.
“Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials”. Diabetes, Obesity & Metabolism16 (1): 48–56. (January 2014). doi:10.1111/dom.12176. PMID23837679.
“Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?”. Regulatory Peptides128 (2): 159–65. (June 2005). doi:10.1016/j.regpep.2004.06.001. PMID15780435.
“Pancreatic safety of incretin-based drugs--FDA and EMA assessment”. The New England Journal of Medicine370 (9): 794–7. (February 2014). doi:10.1056/NEJMp1314078. PMID24571751.
“Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials”. Diabetes, Obesity & Metabolism16 (1): 48–56. (January 2014). doi:10.1111/dom.12176. PMID23837679.